Bayer initiates section III survey to overview aflibercept 8 mg in retinal vein occlusion

10

Would possibly well

2023

Summary

Global section III QUASAR survey will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / See comes after obvious records from the section III PULSAR trial in neovascular (moist) age-linked macular degeneration (nAMD) and section II/III PHOTON trial in diabetic macular edema (DME) / QUASAR is expected to enroll around 800 sufferers in 27 nations / See will add to the sturdy development program for aflibercept 8 mg, exploring the aptitude to attain visual acuity with extended treatment intervals in extra patient populations